AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Phase 2
Completed
- Conditions
- Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT05364931
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AZD2373 subcutaneous injectionDrug: Placebo
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT05351047
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 3
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1035
- Registration Number
- NCT05348577
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
Phase 4
Completed
- Conditions
- HyperkalaemiaChronic Kidney Disease
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (SZC)Drug: Local standard of care
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 186
- Registration Number
- NCT05347693
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
Himalaya Early Access Program
- Conditions
- Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT05345678
- Locations
- 🇺🇸
Research Site, Morgantown, West Virginia, United States
Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab
Phase 1
Completed
- Conditions
- Healthy Participants Study
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT05339100
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 287
- Registration Number
- NCT05329194
- Locations
- 🇺🇸
Research Site, Vancouver, Washington, United States
Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries
Completed
- Conditions
- COVID-19
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 550
- Registration Number
- NCT05315323
- Locations
- 🇦🇪
Research Site, Dubai, United Arab Emirates
REported Outcomes in COPD With Trixeo in Real worlD in Germany
Active, not recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 475
- Registration Number
- NCT05311306
- Locations
- 🇩🇪
Research Site, Zirndorf, Germany
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
Phase 1
Active, not recruiting
- Conditions
- Neurofibromatosis Type 1
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT05309668
- Locations
- 🇪🇸
Research Site, Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath